U.S. Non-oncology Biopharmaceuticals Market Size Share Trends Forecast 2026

1. U.S. NON-ONCOLOGY BIOPHARMACEUTICALS MARKET ANALYSIS INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2020–2027 © Coherent market Insights. All Rights Reserved © Coherent market Insights. All Rights Reserved

2. REPORT DESCRIPTION U.S. Non-oncology Biopharmaceuticals Market - Overview The U.S. Non-oncology Biopharmaceuticals Market, by Product Type (Biologics and Biosimilars), by Drug Class (Monoclonal Erythropoietin, Interferon, Colony-stimulating Factor, Botulinum Toxin, Fusion Protein, Vaccines, Human Recombinant Insulin, Blood Factors, Human Growth Hormone, and Others), and by Disease Indication (Diabetes, Rheumatoid Arthritis, Psoriatic Arthritis, Multiple Sclerosis, Hemophilia, Anemia, Age-related Macular Degeneration, Hepatitis B, Cystic Fibrosis, Osteoporosis, Crohn’s Disease, Ulcerative Colitis, Psoriasis, Ankylosing Spondylitis, and Others (Cardiac Diseases and Others)), was valued at US$ 116.0 Bn in 2018 and is projected to exhibit a CAGR of 10.2% during the forecast period (2018–2026). Antibody, Enzyme Replacement Therapy, Factors such as increasing launch and approval of novel biopharmaceuticals and robust pipeline of biopharmaceutical products in late phase of clinical trial is expected to significantly drive the U.S. non-oncology biopharmaceuticals market growth. For instance, in October 2018, Leadiant Biosciences, Inc. received the U.S. Food and Drug Administration (FDA) approval for its Revcov (elapegademase-lvlr) injection in the U.S. Revcovi is a new enzyme replacement therapy (ERT) for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients. Furthermore, key players are involved in development and launch of novel biopharmaceuticals for new indications. Aimovig was the first human monoclonal antibody approved for treatment of migraine. Browse Research Reports: https://www.coherentmarketinsights.com/market-insight/u-s-non- oncology-biopharmaceuticals-market-2575 © Coherent market Insights. All Rights Reserved

3. REPORT DESCRIPTION Browse 35 Market Data Tables and 38 Figures spread through 224 Pages and in-depth TOC on U.S. Non-oncology Biopharmaceuticals Market, by Product Type (Biologics and Biosimilars), by Drug Class (Monoclonal Antibody, Enzyme Replacement Therapy, Erythropoietin, Interferon, Colony-stimulating Factor, Botulinum Toxin, Fusion Protein, Vaccines, Human Recombinant Insulin, Blood Factors, Human Growth Hormone, and Others), and by Disease Indication (Diabetes, Rheumatoid Arthritis, Psoriatic Arthritis, Multiple Sclerosis, Hemophilia, Anemia, Age-related Macular Degeneration, Hepatitis B, Cystic Fibrosis, Osteoporosis, Crohn’s Disease, Ulcerative Colitis, Psoriasis, Ankylosing Spondylitis, and Others (Cardiac Diseases and Others)) - U.S. Forecast to 2026. Key players in the market are involved in strategic merger, collaboration, acquisition, and partnership for the development of novel biopharmaceuticals to expand its portfolio with strategic acquisition of any company. For instance, in October 2018, Teva Pharmaceutical Industries Ltd. and Celltrion, Inc. entered into an exclusive partnership to commercialize two of Celltrion’s mAb biosimilar candidates in the U.S. and Canada. Risankizumab is an anti-IL-23 monoclonal biologic antibody for psoriasis. Company is also evaluating the product for other indications such as Crohn’s disease, asthma, and psoriatic arthritis. Currently, it is in clinical phase 3. Furthermore, patent loss of blockbuster drugs such as Humira and launch of their biosimilars at low prices is expected to be a major factor negatively affecting the revenue generated by blockbuster drugs, which in turn is expected to negatively affect the overall U.S non-oncology biopharmaceutical market size and growth over the forecast period. Request a Sample copy of this reports: https://www.coherentmarketinsights.com/insight/request-sample/2575 © Coherent market Insights. All Rights Reserved

4. REPORT DESCRIPTION Key Takeaways of the U.S. Non-oncology Biopharmaceuticals Market: The U.S. non-oncology biopharmaceuticals market is expected to exhibit a CAGR of 10.2% during the forecast period (2018 – 2026), owing to increasing product launches and approvals, and robust pipeline of novel U.S. non-oncology biopharmaceuticals The U.S. is the most lucrative economy for monoclonal antibodies, as most of the key players such as AbbVie Inc., Roche Holding AG, and Merck & Co. generate major revenue of their biological drugs from the U.S. In the recent past, various blockbuster biologics such as Humira and Remicade lost patent in the U.S. market. Furthermore, various other high revenue generating biologics are expected to lose their patents in the near future. Loss of patents in the U.S. market offers lucrative opportunity to other players for development of biosimilars. Key players in the market have lucrative opportunities to develop novel and innovative therapies for various rare diseases and target the underserved patients. Acts such as the Orphan Drug Act also supports in creating financial incentives for companies to develop new drugs for rare diseases. Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/2575 © Coherent market Insights. All Rights Reserved

5. ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele. SERVICES CUSTOMIZED RESEARCH INDUSTRY ANALYSIS SYNDICATED RESEARCH COUNTRY SPECIFIC STUDIES MARKET INTELLIGENCE SERVICES CONSULT STUDIES © Coherent market Insights. All Rights Reserved

6. ABOUT CMI SECTOR COVERAGE BIOTECHNOLOGY CLINICAL DIAGNOSTIC HEALTHCARE IT MEDICAL DEVICES MEDICAL IMAGING PHARMACEUTICAL OUR CLIENTS  Global Leading Equipment and System Manufacturers  Marketing Consultancies and the Advertising Industry  Component Providers and System Integrators  Private and Government organization  Distributors, Retailors and Value Added Resellers  Outsourcing Companies  Healthcare IT Solutions Developers  Universities and Business Schools. © Coherent market Insights. All Rights Reserved

7. KEY STATS RESEARCH SOLUTIONS 100+ GLOBAL REPORTS FEASIBILITY STUDIES Insights Published Per Year CUSTOMIZED SOLUTIONS 150+ COUNTRY ANALYSIS Consulting Projects Till Date CONSULT PROJECTS SURVEY RESEARCH 125+ EXCEL FORECAST DATABASE Clients Worldwide Per Year COMPETITIVE ASSESSMENT TECHNOLOGY SNIPPETS 110+ Analysts and Contract Consultants Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved

8. THANK YOU To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: sales@coherentmarketinsights.com For other queries contact: Mr. Shah (Manager - Business Development) Coherent Market Insights sales@coherentmarketinsights.com +1-206-701-6702 © Coherent market Insights. All Rights Reserved